These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10199348)

  • 21. Biogen, Serono squabble over MS market.
    Davidson S
    Nat Biotechnol; 2001 Aug; 19(8):696-7. PubMed ID: 11479543
    [No Abstract]   [Full Text] [Related]  

  • 22. 10 years of interferon beta-1b (Beta feron therapy.
    Kappos L; Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493
    [No Abstract]   [Full Text] [Related]  

  • 23. Transforming multiple sclerosis trials into practical reality.
    Kieseier BC; Wiendl H
    Lancet Neurol; 2011 Jun; 10(6):493-4. PubMed ID: 21571592
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Benatar M
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
    [No Abstract]   [Full Text] [Related]  

  • 25. [Betaferon and therapy of multiple sclerosis--present and future].
    Hohlfeld R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():1. PubMed ID: 11603109
    [No Abstract]   [Full Text] [Related]  

  • 26. Neutralising antibodies against interferon beta in multiple sclerosis.
    Giovannoni G; Deisenhammer F
    Lancet; 2004 Jan; 363(9403):166-7; author reply 168-9. PubMed ID: 14726177
    [No Abstract]   [Full Text] [Related]  

  • 27. Alemtuzumab versus interferon beta-1a: implications for pathology and trial design.
    McFarland HF
    Lancet Neurol; 2009 Jan; 8(1):26-8. PubMed ID: 19081510
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How much can we learn from long-term extension trials in multiple sclerosis?
    Noseworthy JH
    Neurology; 2006 Sep; 67(6):930-1. PubMed ID: 17000954
    [No Abstract]   [Full Text] [Related]  

  • 30. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N; Théorêt G
    Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunosuppressants and multiple sclerosis].
    Ruiz-Peña JL; Izquierdo-Ayuso G
    Rev Neurol; 2002 Aug 16-31; 35(4):373-80. PubMed ID: 12235571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rationale for an early treatment of multiple sclerosis].
    Comi G; Martino G
    Rev Neurol; 2000 Jun 16-30; 30(12):1265-8. PubMed ID: 10935262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uncertain BENEFIT of early interferon beta-1b treatment.
    Pittock SJ
    Lancet Neurol; 2009 Nov; 8(11):970-1. PubMed ID: 19748320
    [No Abstract]   [Full Text] [Related]  

  • 37. [Multiple sclerosis. Not only gait, but thinking is also affected].
    MMW Fortschr Med; 2002 May; Suppl 2():86. PubMed ID: 12070865
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS
    Neurology; 2011 Jan; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interferon-beta treatment for multiple sclerosis and predictors of response].
    Kohriyama T; Ochi K; Matsumoto M
    Nihon Rinsho; 2008 Jun; 66(6):1119-26. PubMed ID: 18540357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corticosteroids in combination therapy for multiple sclerosis.
    Cohen JA
    Lancet Neurol; 2009 Jun; 8(6):502-3. PubMed ID: 19409855
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.